Astellas Pharma Stock Forecast, Price & News

+0.31 (+1.82 %)
(As of 06/18/2021 08:10 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume42,700 shs
Average Volume77,389 shs
Market Capitalization$32.30 billion
P/E Ratio28.44
Dividend Yield1.56%
30 days | 90 days | 365 days | Advanced Chart
Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Astellas Pharma logo

About Astellas Pharma

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.54 out of 5 stars

Medical Sector

368th out of 2,101 stocks

Pharmaceutical Preparations Industry

169th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Astellas Pharma (OTCMKTS:ALPMY) Frequently Asked Questions

What stocks does MarketBeat like better than Astellas Pharma?

Wall Street analysts have given Astellas Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Astellas Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 72,000 shares, an increase of 410.6% from the May 13th total of 14,100 shares. Based on an average trading volume of 95,400 shares, the days-to-cover ratio is presently 0.8 days.
View Astellas Pharma's Short Interest

When is Astellas Pharma's next earnings date?

Astellas Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Astellas Pharma

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Tuesday, April, 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.28. The business had revenue of $2.91 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 11.32% and a net margin of 9.66%.
View Astellas Pharma's earnings history

How has Astellas Pharma's stock price been impacted by Coronavirus?

Astellas Pharma's stock was trading at $15.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPMY stock has increased by 10.4% and is now trading at $17.35.
View which stocks have been most impacted by COVID-19

Is Astellas Pharma a good dividend stock?

Astellas Pharma pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.56%. The dividend payout ratio of Astellas Pharma is 44.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 19.57% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.
View Astellas Pharma's dividend history.

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Astellas Pharma shares split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Who are Astellas Pharma's key executives?

Astellas Pharma's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Representative Director (Age 61, Pay $2.03M)
  • Mr. Naoki Okamura, Corp. Exec. VP, CFO, Chief Strategy Officer & Representative Director
  • Mr. Yoshitsugu Shitaka, Chief Scientific Officer & Pres of Drug Discovery Research
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Catherine B. Levitt, Gen. Counsel
  • Mr. Stig Ogata, VP of Corp. Communications
  • Ms. Collette Taylor, Sr. VP of HR (Age 58)
  • Chihiro Yokota, Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.
  • Dr. Charlotte M. E. Kremer M.D., Mba, Head of Medical Affairs & Exec. VP
  • Mr. Songlin Xue M.D., Ph.D., Head of Pharmacovigilance

Who are some of Astellas Pharma's key competitors?

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $17.35.

How much money does Astellas Pharma make?

Astellas Pharma has a market capitalization of $32.30 billion and generates $11.79 billion in revenue each year. The company earns $1.13 billion in net income (profit) each year or $0.61 on an earnings per share basis.

How many employees does Astellas Pharma have?

Astellas Pharma employs 15,883 workers across the globe.

Does Astellas Pharma have any subsidiaries?

The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.

When was Astellas Pharma founded?

Astellas Pharma was founded in 1923.

What is Astellas Pharma's official website?

The official website for Astellas Pharma is www.astellas.com.

Where are Astellas Pharma's headquarters?

Astellas Pharma is headquartered at 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.

This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.